PDL BioPharma PE Ratio 2006-2020 | PDLI

Current and historical p/e ratio for PDL BioPharma (PDLI) from 2006 to 2020. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. PDL BioPharma PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

PDL BioPharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2020-12-30 2.47 0.00
2020-12-31 2.47 $-1.17 0.00
2020-06-30 2.91 $-1.33 0.00
2020-03-31 2.82 $-0.94 0.00
2019-12-31 3.25 $-0.63 0.00
2019-09-30 2.16 $-0.04 0.00
2019-06-30 3.14 $0.30 10.47
2019-03-31 3.72 $-0.42 0.00
2018-12-31 2.90 $-0.46 0.00
2018-09-30 2.63 $-0.42 0.00
2018-06-30 2.34 $-0.46 0.00
2018-03-31 2.94 $0.69 4.26
2017-12-31 2.74 $0.72 3.81
2017-09-30 3.39 $0.51 6.65
2017-06-30 2.47 $0.45 5.49
2017-03-31 2.27 $0.09 25.22
2016-12-31 2.12 $0.39 5.44
2016-09-30 3.35 $1.06 3.16
2016-06-30 3.14 $1.40 2.24
2016-03-31 3.28 $1.84 1.78
2015-12-31 3.44 $2.00 1.72
2015-09-30 4.69 $1.71 2.74
2015-06-30 5.82 $1.90 3.07
2015-03-31 6.23 $1.95 3.19
2014-12-31 6.68 $1.89 3.54
2014-09-30 6.36 $1.96 3.24
2014-06-30 8.11 $1.71 4.74
2014-03-31 6.85 $1.81 3.79
2013-12-31 6.84 $1.73 3.96
2013-09-30 6.35 $1.68 3.78
2013-06-30 6.04 $1.64 3.68
2013-03-31 5.60 $1.54 3.64
2012-12-31 5.29 $1.47 3.60
2012-09-30 5.68 $1.37 4.14
2012-06-30 4.79 $1.33 3.60
2012-03-31 4.49 $1.19 3.77
2011-12-31 4.27 $1.15 3.72
2011-09-30 3.73 $0.73 5.12
2011-06-30 3.85 $0.69 5.58
2011-03-31 3.71 $0.61 6.08
2010-12-31 3.88 $0.51 7.61
2010-09-30 3.28 $0.86 3.81
2010-06-30 3.20 $0.90 3.56
2010-03-31 3.54 $1.06 3.34
2009-12-31 3.64 $1.14 3.20
2009-09-30 3.34 $1.23 2.72
2009-06-30 3.17 $1.33 2.38
2009-03-31 2.84 $1.11 2.56
2008-12-31 2.31 $0.44 5.24
2008-09-30 2.51 $0.05 50.17
2008-06-30 2.86 $-0.38 0.00
2008-03-31 1.99 $-0.49 0.00
2007-12-31 3.28 $-0.14 0.00
2007-09-30 4.05 $-0.79 0.00
2007-06-30 4.37 $-0.80 0.00
2007-03-31 4.07 $-0.98 0.00
2006-12-31 3.78 $-1.12 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76